Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2026-01-01 @ 3:11 AM
Study NCT ID:
NCT02301156
Status:
COMPLETED
Last Update Posted:
2022-05-20
First Post:
2014-11-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Sponsor:
TG Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01-27
Start Date Type:
ACTUAL
Primary Completion Date:
2020-04-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-04-01
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-20
First Submit QC Date:
None
Study First Post Date:
2014-11-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-04-25
Results First Submit QC Date:
None
Results First Post Date:
2022-05-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-03-26
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-04-25
Last Update Post Date:
2022-05-20
Last Update Post Date Type:
ACTUAL